Prometheus IBD sgi Diagnostic (Prometheus Laboratories Inc.)

HAYES, Inc
Record ID 32017000187
English
Authors' recommendations: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal (GI) tract. IBD is commonly divided into 2 subtypes: Crohn's disease (CD) and ulcerative colitis (UC). IBD has the potential to cause damage to the bowel in the form of inflammation and ulcers, making it pathologically distinct from other gastrointestinal disorders such as irritable bowel syndrome. It is estimated that approximately 10% to 20% of the global population have symptoms of IBD, with 30% of people seeking physician treatment for IBD symptoms. With no established reference standard for IBD diagnosis and subsequent CD and UC diagnoses, clinical findings, such as: patient history, physical examinations, endoscopy, sigmoidoscopy and/or colonoscopy, are used to determine disease status. Established biomarkers and diagnostic tests that identify IBD and distinguish subtypes could provide an alternative to traditional diagnostic factors and may aid with diagnosis and classification. This report reviews 1 such test, the Prometheus IBD sgi Diagnostic.
Details
Project Status: Completed
Year Published: 2017
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Biomarkers
  • Colonic Diseases, Functional
  • Diagnostic Tests, Routine
  • Humans
  • Irritable Bowel Syndrome
  • Laboratories
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.